Why is There Still no Human Vaccine Against Lyme Borreliosis?
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or empirical human data
PubMed 26462328 · doi:10.3409/fb63_3.159
What was done
The author conducted a narrative review examining the biological, clinical, and technological challenges surrounding the development and availability of human vaccines against Lyme borreliosis (Borrelia burgdorferi sensu lato).
What was found
The abstract provides no quantitative data, effect sizes, or statistical comparisons. It reports qualitatively that high antigenic variability among Borrelia outer membrane proteins complicates universal vaccine construction, notes the commercial withdrawal of the OspA vaccine (LYMErix) in the USA, and indicates that future candidates likely require multi-epitope formulations combining vector-borne and spirochetal outer membrane proteins.
Why it matters
This review outlines the immunological and structural obstacles preventing universal Lyme disease vaccination and highlights why multi-antigen strategies are needed while personal protective behavior remains the current standard.
Limits
The abstract reports no primary experimental or clinical human data, no quantitative metrics, and no systematic literature search methodology. Findings reflect a narrative summary and mechanistic reasoning.
Cited by
- context The human Lyme disease vaccine was withdrawn from the market following controversy associated with Andrew Wakefield's fraudulent claims linking vaccines to autism.